Lung cancer treatments may affect your physical and emotional well-being. It’s a good idea to find support as you move through the process. Talk to your cancer care team on how you can go about finding resources and help. Connect with lung cancer support groups. This may be a safe plac...
Rev Prat. 2023; 73(1):7-12 (ISSN: 2101-017X) Lamkhioued M; Pierret T NEW TREATMENTS AND SURVIVAL IN LUNG CANCER. Treatment paradigm for non-squamous cell lung cancer (NSCLC) has evolved dramatically in the early 2000s, mainly because of the identification of targetable oncogenes such ...
Lung cancer represents a major public health problem in the United States and around the world. In the United States alone, more than 175,000 new cases will be diagnosed in 1999, leading to over...doi:10.1007/978-1-59259-093-3_10Gregory A. Masters...
7. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 2015 Mar;87(3):220-5. 8. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet Lond Engl. 2017;389(10066...
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4–17% depending on stage and regional differences. In this...
This growth is reinforced by the National Natural Science Foundation which supports the development of innovative cancer treatments. Germany to be at the Forefront of Lung Cancer Therapeutics with New Product Launches and Smart Solutions The lung cancer therapeutics market in Germany is expanding rapidly...
BRAFTOVI + MEKTOVI now gives adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer a new personalized treatment option Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI
The new numbers from the CDC show the number of cancer deaths will rise most among black women. It also says lung cancer continues to be the biggest killer. But there are some exciting new treatments for lung cancer in our area.
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US...
ArticleOpen access01 February 2023 Main Lung cancer remains the leading cause of cancer-related death, accounting for greater than 20% of all cancer mortalities10. Lung adenocarcinoma (LUAD), a type of non-small cell lung cancer (NSCLC), is the most common subtype and is characterized by dis...